PDK4-IN-1 hydrochloride is an anthraquinone derivative and a potent and orally active pyruvate dehydrogenase kinase 4 (PDK4) inhibitor with an IC50 value of 84 nM. PDK4-IN-1 hydrochloride potently represses cellular transformation and cellular proliferation and induces apoptosis.
RX-3117 (TV-1360) is a potent and orally active anticancer and antimetabolite agent. RX-3117 inhibits DNA methyltransferase 1 (DNMT1). RX-3117 shows antiproliferative and anti-tumour activity. RX-3117 induces cell cycle arrest at S phase and apoptosis.
RX-3117 (TV-1360) is a potent and orally active anticancer and antimetabolite agent. RX-3117 inhibits DNA methyltransferase 1 (DNMT1). RX-3117 shows antiproliferative and anti-tumour activity. RX-3117 induces cell cycle arrest at S phase and apoptosis.
Vandortuzumab vedotin (DSTP 3086S) is an antibody-drug-conjugate to target prostate cancer.
Asunercept (APG101; CAN008) is a soluble CD95-Fc fusion protein targeting CD95L. Asunercept disrupts CD95/CD95L signaling by selectively binding to CD95L. Asunercept can be used in the research of glioblastoma multiforme (GBM), myelodysplastic syndrome (MDS), and graft-versus-host disease (GvHD).
Orexin B, rat, mouse TFA is an endogenous orexin receptor agonist. Orexin B, rat, mouse TFA binds and activates two closely related orphan G protein-coupled receptors OX1-R and OX2-R.
L-Glutamic acid monosodium salt is an agonist at all subtypes of glutamate receptors (metabotropic, kainate, NMDA, and AMPA).
MB-07811 (VK2809) is an orally active, thyroid hormone receptor (THR)-beta agonist that can be used in studies related to hyperlipidemia and nonalcoholic steatohepatitis (NASH).
LY03005 hydrochloride, the hydrochloride form of LY03005, is also a triple reuptake inhibitor that inhibits the reuptake of serotonin, dopamine, and norepinephrine with IC50 values of 723 nM, 491 nM, and 763 nM, respectively.
MB-07811 (VK2809) is an orally active, thyroid hormone receptor (THR)-beta agonist that can be used in studies related to hyperlipidemia and nonalcoholic steatohepatitis (NASH).
MB-07811 (VK2809) is an orally active, thyroid hormone receptor (THR)-beta agonist that can be used in studies related to hyperlipidemia and nonalcoholic steatohepatitis (NASH).
T2AA is a monoubiquitinated proliferating cell nuclear antigen (PCNA) inhibitor that prevents DNA repair, increases double-strand break (DSB) formation and promotes necroptosis and cell cycle arrest in G1 phase.